You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Neoadjuvant treatment.

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Candidates for Neoadjuvant Treatment in Resectable Pancreatic

Completed
  • Pancreatic Cancer
  • Neoadjuvant
  • Neoadjuvant treatment
  • (no location specified)
Nov 9, 2023

Biliary Tract Tumors Trial (Total Neoadjuvant Treatment)

Not yet recruiting
  • Biliary Tract Neoplasms
  • Total Neoadjuvant Treatment
  • (no location specified)
Sep 7, 2023

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

Recruiting
  • Non-Small Cell Lung Cancer
  • Neoadjuvant immunochemotherapy
  • Neoadjuvant chemotherapy
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital,Chinese Academy of Medica
Aug 1, 2023

Thymic Carcinoma Trial in Shanghai (Envolizumab combined with radiotherapy)

Recruiting
  • Thymic Carcinoma
  • Envolizumab combined with radiotherapy
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Sep 3, 2023

Osteosarcoma Trial (Surufatinib plus chemo, Chemotherapy)

Not yet recruiting
  • Osteosarcoma
  • (no location specified)
Jun 29, 2023

Hepatocellular Carcinoma Resectable Trial in Fuzhou (neoadjuvant therapy)

Not yet recruiting
  • Hepatocellular Carcinoma Resectable
  • neoadjuvant therapy
  • Fuzhou, Fujian, China
    The First Affiliated Hospital of Fujian Medical University
Aug 19, 2023

Rectal Cancer Trial in Bergen (On-couch adaptive radiotherapy)

Not yet recruiting
  • Rectal Cancer
  • On-couch adaptive radiotherapy
  • Bergen, Norway
    Haukeland University Hospital
May 22, 2023

Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

Not yet recruiting
  • Colorectal Cancer
  • Serplulimab + FOLFOXIRI
  • Radiation therapy
  • (no location specified)
Oct 24, 2023

Locally Advanced Cervical Cancer Trial in Xi'an (Zimberelimab, Albumin-bound Paclitaxel, Cisplatin)

Recruiting
  • Locally Advanced Cervical Cancer
  • Xi'an, Shaanxi, China
    Hongxi Zhao
Sep 20, 2023

Pheochromocytoma, Paraganglioma Trial in Beijing (Temozolomide)

Recruiting
  • Pheochromocytoma
  • Paraganglioma
  • Beijing, China
    Peking Union Medical College Hospital
May 22, 2023

Rectal Cancer by MRI-guided Radiotherapy

Not yet recruiting
  • Rectal Cancer
  • Radiotherapy with MRIdian with simultaneous integrated boost
  • Questionnaires before, during and after radiotherapy
  • (no location specified)
Jun 13, 2023

Carcinoma, Cervix Carcinoma Trial in Fuzhou (Karelizumab combined with etoposide and cisplatin)

Not yet recruiting
  • Carcinoma
  • Cervix Carcinoma
  • Karelizumab combined with etoposide and cisplatin
  • Fuzhou, Fujian, China
    Fujian Cancer Hospital
Jun 9, 2023

Breast Cancer, Neoadjuvant Therapy Trial in Beijing (Utidelone, Carboplatin, Epirubicin)

Not yet recruiting
  • Breast Cancer
  • Neoadjuvant Therapy
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Aug 1, 2023

Differentiated Thyroid Cancer Trial in Shanghai (surufatinib)

Recruiting
  • Differentiated Thyroid Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 9, 2023

Pheochromocytoma, Paraganglioma Trial in Beijing (Anlotinib HCl)

Recruiting
  • Pheochromocytoma
  • Paraganglioma
  • Anlotinib hydrochloride
  • Beijing, China
    Peking Union Medical College Hospital
May 22, 2023

Neoadjuvant, Immunotherapy, Sarcoma,Soft Tissue Trial in Warsaw (Pembrolizumab, Eftilagimod alpha)

Recruiting
  • Neoadjuvant
  • +3 more
  • Pembrolizumab, Eftilagimod alpha
  • Warsaw, Poland
    Maria Sklodowska-Curie National Research Institute of Oncology
Nov 7, 2023

HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)

Not yet recruiting
  • HER2 Low Breast Carcinoma
  • SHR-A1811 for injection
  • (no location specified)
Jun 12, 2023

Response After Neoadjuvant Treatment of Locally Advanced Rectal

Not yet recruiting
  • Rectal Cancer
  • PET-MRI
  • Strasbourg, France
    Institut de cancérologie Strasbourg Europe
Mar 15, 2023

Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab Trial in Beijing (Pembrolizumab, Cisplatin,

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Beijing, Beijing, China
    Beijing Tongren Hospital
Oct 26, 2023

Sintilimab and Anlotinib in Combination With Chemo Trial in Xi'an (Sintilimab and anlotinib in combination with chemo)

Completed
  • Sintilimab and Anlotinib in Combination With Chemotherapy
  • Sintilimab and anlotinib in combination with chemotherapy
  • Xi'an, Shanxi, China
  • +1 more
Aug 27, 2023

Esophageal Squamous Cell Cancer Trial in Beijing (Toripalimab, Paclitaxel, Cisplatin)

Recruiting
  • Esophageal Squamous Cell Cancer
  • Beijing, Beijing, China
    Beijing Cancer Hospital / Peking University Cancer Hospital
Jan 30, 2023

Locally Advanced Colorectal Carcinoma Trial in Beijing (Cadonilimab, FOLFOX regimen)

Recruiting
  • Locally Advanced Colorectal Carcinoma
  • Beijing, Beijing, China
    Cancer Hospital/ National Cancer Center, Chinese Academy of Medi
Nov 23, 2023

Soft Tissue Sarcoma Trial in Zhengzhou (Piamprimab (AK105))

Not yet recruiting
  • Soft Tissue Sarcoma
  • Piamprimab (AK105)
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jan 30, 2023

MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

Not yet recruiting
  • MSI-H
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 26, 2023

pMMR, MSS, MSI-L Trial (Serplilumab, Capecitabine, Oxaliplatin)

Not yet recruiting
  • pMMR
  • +3 more
  • (no location specified)
Feb 19, 2023